Efficacy of PPV23 in Older Adults

In a prospective, observational study among individuals aged ≥60, immunization with the 23-valent pneumococcal vaccine within 5 years was associated with significantly reduced risk for community-acquired pneumonia.

Although the 23-valent pneumococcal vaccine (PPV23) is recommended for high-risk and older adults, its efficacy in preventing community-acquired pneumonia (CAP) remains controversial. To determine the clinical benefits of PPV23 use, researchers performed a closed population–based prospective cohort study in Catalonia, Spain, where vaccination with PPV23 has been recommended since 2002 for people aged ≥60.

A total of 27,204 individuals aged ≥60 were followed from December 2008 through November 2011. The primary outcomes were hospitalization for CAP (pneumococcal or all-cause) and death from any cause.

The overall incidence rates per 1000 person-years were 0.21 for bacteremic pneumococcal CAP, 1.45 for nonbacteremic pneumococcal CAP, 7.51 for a…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Efficacy of PPV23 in Older Adults

Topics

Reviewing Author